This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jean Revuz, MD; Jean-Claude Guillaume, MD; Michel Janier, MD; Pierrick Hans, MD; Claudine Marchand, MD; Pierre Souteyrand, MD; Jean-Marie Bonnetblanc, MD; Alain Claudy, MD; Sophie Dallac, MD; C. Klene, MD; Béatrice Crickx, MD; Hélène Sancho-Garnier, MD; J. C. Chaumeil, PhD

Arch Dermatol. 1990;126(7):923-927.

Abstract
• A multicentric crossover randomized trial of 100 mg of thalidomide vs placebo each for 2 months was conducted in patients with severe aphthous stomatitis of more than 6 months' duration. Seventy-three patients were included. Complete remission was obtained in 32 patients who received thalidomide and in 6 patients who received placebo. The confidence interval of the difference between the two treatments ranged from 25% to 53%. Most of the patients who did not achieve a complete remission had a dramatic improvement with regard to the number of aphthae when they were receiving thalidomide. Thirteen of 17 patients who had a complete remission while they were receiving thalidomide had a recurrence with placebo, 19 ± 9 (mean ± SD) days after stopping this drug. Side effects were significantly more frequent with thalidomide, especially drowsiness and constipation. We concluded that thalidomide in a dosage of 100 mg/d is an effective treatment of severe aphthous stomatitis but is not without some risk.

(Arch Dermatol. 1990;126:923-927)

Author Affiliations
From the Services de Dermatologie, Centre Hôpitalier Universitaire Henri Mondor, Créteil, France (Drs Revuz and Guillaume), CHU St Louis, Paris, France (Dr Janier), CHU de Bordeaux (France) (Drs Hans and Klene), CHU de Lyons (France) (Dr Marchand), CHU deClermont Ferrand (France) (Dr Souteyrand), CHU de Limoges (Dr Bonnetblanc), CHU St-Etienne (Dr Claudy), CHU Dijon (France) (Dr Dallac), and CHU Bichat, Paris, France (Dr Crickx); the Service des Statistiques, Institut Gustave Roussy, Villejuif, France (Dr Sancho-Garnier), and the Pharmacie Centrale des Hôpitaux de l'Assistance Publique, Paris, France (Dr Chaumeil).

Footnotes
Accepted for publication February 15, 1990.

Presented at the Franco-British Reunion, Cambridge, England, July 5, 1989.

Reprint requests to Service de Dermatologie, Hôpital Henri Mondor, 94000 Créteil, France (Dr Revuz).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Randomized, Double-blind, Placebo-Controlled Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis
Thornhill et al.
Arch Dermatol 2007;143:463-470.
ABSTRACT | FULL TEXT  

New and Old Therapeutics for Oral Ulcerations
Bruce and Rogers
Arch Dermatol 2007;143:519-523.
FULL TEXT  

Clinical practice. Aphthous ulceration.
Scully
NEJM 2006;355:165-172.
FULL TEXT  

The Behcet's Disease Activity Index
Lawton et al.
Rheumatology (Oxford) 2004;43:73-78.
ABSTRACT | FULL TEXT  

Recalcitrant, Recurrent Aphthous Stomatitis Treated With Etanercept
Robinson and Guitart
Arch Dermatol 2003;139:1259-1262.
FULL TEXT  

Thalidomide and its derivatives: emerging from the wilderness
Gordon and Goggin
Postgrad. Med. J. 2003;79:127-132.
ABSTRACT | FULL TEXT  

American Experience With Low-Dose Thalidomide Therapy for Severe Cutaneous Lupus Erythematosus
Duong et al.
Arch Dermatol 1999;135:1079-1087.
ABSTRACT | FULL TEXT  

Behcet's disease: evaluation of a new instrument to measure clinical activity
Bhakta et al.
Rheumatology (Oxford) 1999;38:728-733.
ABSTRACT | FULL TEXT  

Recurrent Aphthous Stomatitis
Porter et al.
CROBM 1998;9:306-321.
ABSTRACT | FULL TEXT  

Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection
Jacobson et al.
NEJM 1997;336:1487-1493.
ABSTRACT | FULL TEXT  

Crossover Study of Thalidomide vs Placebo in Jessner's Lymphocytic Infiltration of the Skin
Guillaume et al.
Arch Dermatol 1995;131:1032-1035.
ABSTRACT  

In Vitro Activity of Thalidomide Against Mycobacterium avium Complex
Vicente et al.
Arch Intern Med 1993;153:534-534.
ABSTRACT  

Thalidomide in Patients With Acquired Immunodeficiency Syndrome
Bouza et al.
Arch Intern Med 1992;152:1089-1090.
ABSTRACT  

Acyclovir in the Prevention of Severe Aphthous Ulcers
Pedersen
Arch Dermatol 1992;128:119-120.
ABSTRACT